Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Andrew Regan Ph.D.
Palo Alto +1 650 632 4736 aregan@cov.com Download V-card

Dr. Andrew Regan focuses on the protection and maintenance of Orange Book pharmaceutical patents, including their assertion against ANDA filers, and their defense against post-issuance review proceedings at the Patent Office. Most recently he was part of the litigation and trial team representing Indivior, winning a major victory in its bet-the-company patent litigation related to the blockbuster Suboxone® Film product.

Before practicing law, Dr. Regan was a research scientist. During his tenure at Cornell University, he was a National Institutes of Health (NIH) fellow in molecular virology and pathogenesis and published numerous peer-reviewed studies in the field of infectious disease.

  • Represented AstraZeneca in defeating Complex Innovations’ attack on a patent covering SYMBICORT® inhalation aerosol for asthma and COPD. On July 24, 2017, the Patent Trial and Appeal Board denied institution of an IPR trial as to every challenged claim. The PTAB largely followed the arguments Covington presented in the preliminary response when determining that the petition failed to demonstrate a reasonable likelihood of prevailing at trial.
  • Representing Indivior in multiple bet-the-company patent litigation disputes related to its billion dollar Suboxone® Film product. Secured major bench trial victory in 2016 against first two ANDA filers.